At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Ultratrace Iobenguane (MIBG) I 131drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
In Brief
A Phase 2 clinical trial evaluating Ultratrace Iobenguane (MIBG) I 131 for Pheochromocytoma and Paraganglioma. Completed, enrolled 24 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPheochromocytoma, Paraganglioma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedApr 2007
Primary CompletionJun 2009
Study CompletionJun 2011
TodayJul 2026
First PostedApr 11, 2007
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2009
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.2 years ago
Interventions
Ultratrace Iobenguane (MIBG) I 131drug
Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose